Olema Oncology to Present at Canaccord Genuity 41st Annual Growth Conference
July 28 2021 - 4:05PM
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq:
OLMA), a clinical-stage biopharmaceutical company focused on the
discovery, development and commercialization of targeted therapies
for women’s cancers, today announced that Sean P. Bohen, M.D.,
Ph.D., President and Chief Executive Officer, will present at the
Canaccord Genuity 41st Annual Growth Conference, being held
virtually on Wednesday, August 11, 2021 at 3:00 p.m. ET (12:00 p.m.
PT).
A live webcast of the presentation may be accessed under the
Investors & Media section of Olema’s website (www.olema.com)
and will be archived for 14 days.
About Olema OncologyOlema Oncology is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of targeted therapies for women’s
cancers. Olema’s lead product candidate, OP-1250, is an
orally-available small molecule with combined activity as both a
complete estrogen receptor (ER) antagonist (CERAN) and a selective
ER degrader (SERD). It is currently being evaluated as a single
agent in an ongoing Phase 1/2 clinical trial in patients with
recurrent, locally advanced or metastatic ER-positive (ER+), human
epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Olema is headquartered in San Francisco.
Contact:Eva StroynowskiVice President, Communications and
Investor Relationseva@olema.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Aug 2023 to Aug 2024